Steve Harris v. Amgen, Inc.

CourtCourt of Appeals for the Ninth Circuit
DecidedJuly 14, 2009
Docket08-55389
StatusPublished

This text of Steve Harris v. Amgen, Inc. (Steve Harris v. Amgen, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Steve Harris v. Amgen, Inc., (9th Cir. 2009).

Opinion

FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

STEVE HARRIS; DENNIS F. RAMOS,  On Behalf of Themselves and All Others Similarly Situated, Plaintiffs-Appellants, v. AMGEN, INC.; FRANK J. BIONDI, JR.; No. 08-55389 JERRY D. CHOATE; FRANK C. D.C. No. HERRINGER; GILBERT S. OMENN;  2:07-cv-05442-PSG- DAVID BALTIMORE; JUDITH C. PLA PELHAM; KEVIN W. SHARER; OPINION FREDERICK W. GLUCK; LEONARD D. SCHAEFFER; ROBERT A. BRADWAY; RETIREMENT BENEFITS COMMITTEE OF THE BOARD OF DIRECTORS OF AMGEN, Defendants-Appellees.  Appeal from the United States District Court for the Central District of California Philip S. Gutierrez, District Judge, Presiding

Argued and Submitted May 8, 2009—Pasadena, California

Filed July 14, 2009

Before: Betty B. Fletcher, Raymond C. Fisher, and Ronald M. Gould, Circuit Judges.

Opinion by Judge Gould

8819 8822 HARRIS v. AMGEN, INC.

COUNSEL

Francis M. Gregorek, Betsy C. Manifold, Rachele R. Rickert, and Mark C. Rifkin (argued), Wolf Haldenstein Adler Free- man & Herz LLP, San Diego, California, and Thomas J. McKenna, Gainey & McKenna, New York, New York, for the plaintiffs-appellants.

Steven O. Kramer, John Nadolenco, Mack Anderson, Robert P. Davis (argued), and Michele L. Odorizzi, Mayer Brown LLP, Los Angeles, California, for the defendants-appellees.

OPINION

GOULD, Circuit Judge:

Steve Harris and Dennis F. Ramos (collectively, “Plain- tiffs”) sued Amgen, Inc. (“Amgen”) and several Amgen direc- tors and officers, alleging that the defendants breached their fiduciary duties under the Employee Retirement Income Security Act (“ERISA”) in their operation of two ERISA retirement plans. The district court dismissed Harris’s claims on the ground that he lacked standing as an ERISA plan “par- ticipant” because he had withdrawn all of his assets from his plan. It also dismissed Ramos’s claims, reasoning that although Ramos had standing, he did not allege any claims against defendants who were fiduciaries under the plan. The HARRIS v. AMGEN, INC. 8823 district court then denied Plaintiffs leave to amend their com- plaint.

We reverse the dismissal of Plaintiffs’ complaint. We hold that Harris has standing as an ERISA plan participant to seek relief under ERISA § 502(a)(2), codified at 29 U.S.C. § 1132(a)(2), despite having withdrawn all of his assets from his plan. We also conclude that the district court improperly denied Plaintiffs leave to amend their complaint to add more factual allegations where necessary and to identify proper fiduciaries of the Plaintiffs’ ERISA plans.

I

Amgen is a publicly traded biotechnology company that operates Amgen Manufacturing, Ltd. (“Amgen Manufactur- ing”) as a wholly owned subsidiary. Employees of Amgen are entitled to participate in the Amgen Retirement and Savings Plan (the “Amgen Plan”), and Amgen Manufacturing employ- ees may participate in the Retirement and Savings Plan for Amgen Manufacturing, Ltd. (the “Manufacturing Plan”). Each Plan is a “defined contribution plan,” defined as “a pen- sion plan which provides for an individual account for each participant and for benefits based solely upon the amount con- tributed to the participant’s account.” 29 U.S.C. § 1002(34).1

Amgen is a “named fiduciary” only of the Amgen Plan,2 and Amgen Manufacturing is a named fiduciary only of the Manufacturing Plan. The Amgen Plan allows the Amgen Board of Directors (the “Board”) to delegate management and administration of the Plan to a “Fiduciary Committee.” Dur- 1 A defined contribution plan is distinct from a “defined benefit plan,” which, with exceptions not relevant here, “means a pension plan other than an individual account plan.” 29 U.S.C. § 1002(35). 2 A named fiduciary is “a fiduciary who is named in the plan instrument” or by an authorized employer or employee organization. 29 U.S.C. § 1102(a)(2). 8824 HARRIS v. AMGEN, INC. ing the time relevant to this appeal, fiduciary responsibilities for both Plans were delegated to the Fiduciary Committee.

Steve Harris worked at Amgen until January 2007 and par- ticipated in the Amgen Plan. His Amgen Plan holdings some- times included Amgen stock. Harris withdrew his assets from his Amgen Plan account in July 2007. Dennis F. Ramos worked at Amgen Manufacturing until March 2007, partici- pating in the Manufacturing Plan. His Manufacturing Plan holdings also sometimes included Amgen Stock. Ramos still has assets in the Manufacturing Plan.

In August 2007 Harris and Ramos filed a class action com- plaint (the “Complaint”), alleging that during a 22-month class period the defendants breached their fiduciary duties by allowing the Plans to purchase and hold Amgen stock while knowing that the stock price was artificially inflated because of improper off-label drug marketing and sales. The Com- plaint asserts that the Amgen stock price declined signifi- cantly once the off-label activity became public, and Harris and Ramos claim that the defendants are liable for the result- ing losses suffered by the class members. The Complaint sought relief under ERISA § 502(a)(2) (“Section 502(a)(2)”), codified at 29 U.S.C. § 1132(a)(2), which authorizes a suit by a plan participant “for appropriate relief” against a plan fidu- ciary for breach of fiduciary duty.

The Complaint names as defendants Amgen, Amgen’s chief financial officer, and nine Amgen Board members (col- lectively, “Defendants”). Neither Amgen Manufacturing nor the Fiduciary Committee is named as a defendant. However, the Complaint does assert claims against a “Retirement Bene- fits Committee of the Board of Directors of Amgen,” which it claims has fiduciary responsibilities over both Plans.

Defendants filed a motion to dismiss for lack of subject matter jurisdiction under Federal Rule of Civil Procedure (“Rule”) 12(b)(1), and for failure to state a claim under Rule HARRIS v. AMGEN, INC. 8825 12(b)(6). The district court granted the motion and dismissed with prejudice all of Harris’s claims, concluding that Harris did not have statutory standing as a “participant” in the Amgen Plan because he had already cashed out of his Plan account. The district court determined that Ramos had stand- ing because he still had assets in the Manufacturing Plan, but it dismissed with prejudice all of Ramos’s claims on the ground that neither Amgen, the alleged retirement committee, nor the named defendants were fiduciaries of the Manufactur- ing Plan.

The district court also denied Plaintiffs’ request for leave to amend their Complaint. The district court reasoned that Harris could not cure his lack of standing through amendment and that Ramos did not “have a viable claim against the named defendants.” The district court expressly made “no determina- tion as to whether Plaintiffs have a viable claim against Amgen Manufacturing or the members of the Fiduciary Com- mittee.” Harris and Ramos appeal the dismissal of their claims and the denial of leave to amend.

II

A

We first consider whether the district court properly deter- mined that Harris lacked standing under Section 502(a)(2) because he had withdrawn his assets from the Amgen Plan. We review questions of standing under ERISA de novo. Stew- art v. Thorpe Holding Co.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Massachusetts Mutual Life Insurance v. Russell
473 U.S. 134 (Supreme Court, 1985)
Firestone Tire & Rubber Co. v. Bruch
489 U.S. 101 (Supreme Court, 1989)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Pegram v. Herdrich
530 U.S. 211 (Supreme Court, 2000)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
LaRue v. DeWolff, Boberg & Associates, Inc.
552 U.S. 248 (Supreme Court, 2008)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Evans v. Akers
534 F.3d 65 (First Circuit, 2008)
Richard P. Kuntz v. Nat J. Reese
785 F.2d 1410 (Ninth Circuit, 1986)
In Re Mutual Funds Investment Litigation
529 F.3d 207 (Fourth Circuit, 2008)
Vaughn v. Bay Environmental Management, Inc.
567 F.3d 1021 (Ninth Circuit, 2009)
Paulsen v. CNF INC.
559 F.3d 1061 (Ninth Circuit, 2009)
Graden v. Conexant Systems Inc.
496 F.3d 291 (Third Circuit, 2007)
Poore v. Simpson Paper Co.
566 F.3d 922 (Ninth Circuit, 2009)
Bowles v. Reade
198 F.3d 752 (Ninth Circuit, 1999)
Lee v. City of Los Angeles
250 F.3d 668 (Ninth Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
Steve Harris v. Amgen, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/steve-harris-v-amgen-inc-ca9-2009.